首页> 外文期刊>Advances in Experimental Medicine and Biology >Preoperative Stress Conditioning in Humans: Is Oxygen the Drug of Choice?
【24h】

Preoperative Stress Conditioning in Humans: Is Oxygen the Drug of Choice?

机译:人类的术前应力调理:是氧气的选择药物吗?

获取原文
获取原文并翻译 | 示例
           

摘要

Complications following invasive medical and surgical procedures are common and costly. No clinical protocols exist to actively condition patients prior to these high risk interventions. Effective preconditioning algorithms have been repeatedly demonstrated in animal models for more than a quarter century, where brief exposures to hyperthermia (heat shock), ischemia (ischemic preconditioning) or hypoxia have been employed. Heat shock pretreatment confers protection against experimental acute ischemia-reperfusion, endotoxin challenge and other stressors. The resulting state of protection is short lived (hours) and is associated with new gene expression, typical of a cell stress response (CSR). We aim to use the CSR to actively precondition patients before surgery, a process termed stress conditioning (SC). SC is a procedure in which tissues are briefly exposed to a conditioning stressor and recovered to permit the development of a transient state of resistance to ischemia-reperfusion injury. Successful SC of humans prior to surgery may reduce postoperative complications related to periods of hypotension, hypoxia, or ischemia. Stressors such as heat shock, acute ischemia, endotoxin, heavy metals or hypoxia can induce this protected state but are themselves harmful and of limited clinical utility. The identification of a stressor that could induce the CSR in a non-harmful manner seemed unlikely, until high dose oxygen was considered. Human microvascular endothelial cells (HMEC-1) exposed to high dose oxygen at 2.4 ATA x 60-90 min developed increased resistance to an oxidant challenge in vitro (peroxide). The molecular changes described here, together with our understanding of the CSR and SC phenomena, suggest high dose oxygen may be the drug of choice for clinical preconditioning protocols and should be systematically tested in clinical trials. Oxygen dosing includes the following ranges: room air exposure is 0.21 ATA, clinical oxygen therapy 0.3-1.0 ATA (normobaric hyperoxia) and hyperbaric oxygen is 1.5-3.0 ATA (ATA-atmosphere absolute).
机译:侵入性医疗和外科手术后的并发症是常见的且昂贵的。在这些高风险干预措施之前,不存在临床方案来激发患者。有效的预处理算法在动物模型中一再展示超过四分之一世纪,其中对高温(热休克)短暂暴露(热休克),缺血(缺血预处理)或缺氧。热休克预处理赋予实验性急性缺血再灌注,内毒素攻击和其他压力源的保护。产生的保护状态短寿命(小时),与新的基因表达相关,典型的细胞应激响应(CSR)。我们的目标是在手术前使用CSR激发前提患者,该过程称为应力调理(SC)。 SC是一种过程,其中组织短暂地暴露于调理应激源,并回收以允许开发耐缺血再灌注损伤的瞬态状态。手术前的人类的成功SC可以减少与低血压,缺氧或缺血的术后并发症。热休克,急性缺血,内毒素,重金属或缺氧等压力源可以诱导这种受保护状态,但本身是有害的,临床效用有限。鉴定以非有害方式诱导CSR的压力源似乎不太可能,直到考虑高剂量氧气。将人的微血管内皮细胞(HMEC-1)暴露于高剂量氧气,在2.4 ATA×60-90分钟内产生增加对体外(过氧化物)的氧化剂攻击的增加。这里描述的分子变化以及我们对CSR和SC现象的理解,表明高剂量氧可能是临床预处理方案的首选药物,并且应在临床试验中进行系统地测试。氧气剂量包括以下范围:室内空气暴露为0.21 ATA,临床氧疗法0.3-1.0 ATA(正常性高氧)和高压氧为1.5-3.0 ATA(ATA-大气绝对)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号